美托洛尔联合辛伐他汀在急性心肌梗死早期溶栓治疗中的应用价值分析

目的:探讨美托洛尔联合辛伐他汀在急性心肌梗死早期溶栓治疗中的应用价值。方法:选择2016年1月-2017年7月80例急性心肌梗死患者分组。对照组采用早期溶栓治疗+美托洛尔+普伐他汀治疗,观察组采用早期溶栓治疗+美托洛尔+辛伐他汀治疗。比较两组急性心肌梗死转归率;心因性死亡发生率、再发梗死率;干预前后患者心功能、QRS积分。结果:观察组急性心肌梗死转归率高于对照组,P<0.05;观察组心因性死亡发生率、再发梗死率低于对照组,P<0.05;干预前两组心功能、QRS积分相近,P>0.05;干预后观察组心功能、QRS积分优于对照组,P<0.05。结论:美托洛尔联合辛伐他汀在急性心肌梗死早期溶栓治疗中的应用价值高,可降低心因性死亡发生率、再发梗死率,改善患者心功能和临床症状,值得推广。

Objective:To investigate the value of metoprolol combined with simvastatin in early thrombolytic therapy of acute myocardial infarction.Methods:From January 2016 to July 2017,80 patients with acute myocardial infarction were divided into groups.The control group was treated with early thrombolysis+metoprolol+pravastatin.The observation group was treated with early thrombolysis+metoprolol+simvastatin.The prognosis of acute myocardial infarction was compared between the two groups;the incidence of cardiac death and recurrent infarction rate;heart function and QRS score before and after intervention.Results:The prognosis of acute myocardial infarction in observation group was higher than that in control group(P<0.05).The incidence of cardiac death and relapse infarction rate in observation group was lower than that in control group(P<0.05).Before intervention,heart function,QRS score(P>0.05).After intervention,heart function and QRS score in observation group were better than those in control group(P<0.05).Conclusion:Metoprolol combined with simvastatin has high value in the early thrombolytic therapy of acute myocardial infarction,which can reduce the incidence of cardiac death,recurrent infarction rate and improve the cardiac function and clinical symptoms of patients with myocardial infarction.It is worth promoting.